Efficacy of postoperative anticoagulation therapy with enoxaparin for portal vein thrombosis after hepatic resection in patients with liver cancer

Yo Ichi Yamashita, Yuki Bekki, Daisuke Imai, Toru Ikegami, Tomoharu Yoshizumi, Tetsuo Ikeda, Hirofumi Kawanaka, Akihiro Nishie, Ken Shirabe, Yoshihiko Maehara

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Backgrounds: Enoxaparin, low-molecular-weight heparin, has become a routine thromboprophylaxis in general surgery. Study design: A retrospective cohort study was performed in 281 patients who underwent hepatic resections for liver cancers from 2011 to 2013. These patients were divided into two groups; an enoxaparin (-) group (n = 228) and an enoxaparin (+) group (n = 53). Short-term surgical results including venous thromboembolism (VTE) and portal vein thrombosis (PVT) were compared. Results: In the enoxaparin (+) group, the patients' age (65 vs. 69 years; p = 0.01) and BMI (22.9 vs. 24.4; p < 0.01) were significantly higher. According to the symptomatic VTE, symptomatic pulmonary embolism occurred in one patient (0.4%) in the enoxaparin (-) group, but the complication rate was not significantly different (p = 0.63). The complication rate of PVT was significantly lower in the enoxaparin (+) group (10 vs. 2%; p = 0.04). The independent risk factors for PVT were an operation time ≥ 300 minutes (Odds ratio 6.66) and non-treatment with enoxaparin (Odds ratio 2.49). Conclusions: Postoperative anticoagulant therapy with enoxaparin could prevent PVT in patients who underwent hepatic resection for liver cancers.

Original languageEnglish
Pages (from-to)826-831
Number of pages6
JournalThrombosis Research
Volume134
Issue number4
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Enoxaparin
Liver Neoplasms
Portal Vein
Thrombosis
Liver
Venous Thromboembolism
Therapeutics
Odds Ratio
Low Molecular Weight Heparin
Pulmonary Embolism
Anticoagulants
Cohort Studies
Retrospective Studies
Age Groups

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Efficacy of postoperative anticoagulation therapy with enoxaparin for portal vein thrombosis after hepatic resection in patients with liver cancer. / Yamashita, Yo Ichi; Bekki, Yuki; Imai, Daisuke; Ikegami, Toru; Yoshizumi, Tomoharu; Ikeda, Tetsuo; Kawanaka, Hirofumi; Nishie, Akihiro; Shirabe, Ken; Maehara, Yoshihiko.

In: Thrombosis Research, Vol. 134, No. 4, 01.10.2014, p. 826-831.

Research output: Contribution to journalArticle

Yamashita, Yo Ichi ; Bekki, Yuki ; Imai, Daisuke ; Ikegami, Toru ; Yoshizumi, Tomoharu ; Ikeda, Tetsuo ; Kawanaka, Hirofumi ; Nishie, Akihiro ; Shirabe, Ken ; Maehara, Yoshihiko. / Efficacy of postoperative anticoagulation therapy with enoxaparin for portal vein thrombosis after hepatic resection in patients with liver cancer. In: Thrombosis Research. 2014 ; Vol. 134, No. 4. pp. 826-831.
@article{d6f7d567c9aa47beba18edc20c001f57,
title = "Efficacy of postoperative anticoagulation therapy with enoxaparin for portal vein thrombosis after hepatic resection in patients with liver cancer",
abstract = "Backgrounds: Enoxaparin, low-molecular-weight heparin, has become a routine thromboprophylaxis in general surgery. Study design: A retrospective cohort study was performed in 281 patients who underwent hepatic resections for liver cancers from 2011 to 2013. These patients were divided into two groups; an enoxaparin (-) group (n = 228) and an enoxaparin (+) group (n = 53). Short-term surgical results including venous thromboembolism (VTE) and portal vein thrombosis (PVT) were compared. Results: In the enoxaparin (+) group, the patients' age (65 vs. 69 years; p = 0.01) and BMI (22.9 vs. 24.4; p < 0.01) were significantly higher. According to the symptomatic VTE, symptomatic pulmonary embolism occurred in one patient (0.4{\%}) in the enoxaparin (-) group, but the complication rate was not significantly different (p = 0.63). The complication rate of PVT was significantly lower in the enoxaparin (+) group (10 vs. 2{\%}; p = 0.04). The independent risk factors for PVT were an operation time ≥ 300 minutes (Odds ratio 6.66) and non-treatment with enoxaparin (Odds ratio 2.49). Conclusions: Postoperative anticoagulant therapy with enoxaparin could prevent PVT in patients who underwent hepatic resection for liver cancers.",
author = "Yamashita, {Yo Ichi} and Yuki Bekki and Daisuke Imai and Toru Ikegami and Tomoharu Yoshizumi and Tetsuo Ikeda and Hirofumi Kawanaka and Akihiro Nishie and Ken Shirabe and Yoshihiko Maehara",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.thromres.2014.07.038",
language = "English",
volume = "134",
pages = "826--831",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Efficacy of postoperative anticoagulation therapy with enoxaparin for portal vein thrombosis after hepatic resection in patients with liver cancer

AU - Yamashita, Yo Ichi

AU - Bekki, Yuki

AU - Imai, Daisuke

AU - Ikegami, Toru

AU - Yoshizumi, Tomoharu

AU - Ikeda, Tetsuo

AU - Kawanaka, Hirofumi

AU - Nishie, Akihiro

AU - Shirabe, Ken

AU - Maehara, Yoshihiko

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Backgrounds: Enoxaparin, low-molecular-weight heparin, has become a routine thromboprophylaxis in general surgery. Study design: A retrospective cohort study was performed in 281 patients who underwent hepatic resections for liver cancers from 2011 to 2013. These patients were divided into two groups; an enoxaparin (-) group (n = 228) and an enoxaparin (+) group (n = 53). Short-term surgical results including venous thromboembolism (VTE) and portal vein thrombosis (PVT) were compared. Results: In the enoxaparin (+) group, the patients' age (65 vs. 69 years; p = 0.01) and BMI (22.9 vs. 24.4; p < 0.01) were significantly higher. According to the symptomatic VTE, symptomatic pulmonary embolism occurred in one patient (0.4%) in the enoxaparin (-) group, but the complication rate was not significantly different (p = 0.63). The complication rate of PVT was significantly lower in the enoxaparin (+) group (10 vs. 2%; p = 0.04). The independent risk factors for PVT were an operation time ≥ 300 minutes (Odds ratio 6.66) and non-treatment with enoxaparin (Odds ratio 2.49). Conclusions: Postoperative anticoagulant therapy with enoxaparin could prevent PVT in patients who underwent hepatic resection for liver cancers.

AB - Backgrounds: Enoxaparin, low-molecular-weight heparin, has become a routine thromboprophylaxis in general surgery. Study design: A retrospective cohort study was performed in 281 patients who underwent hepatic resections for liver cancers from 2011 to 2013. These patients were divided into two groups; an enoxaparin (-) group (n = 228) and an enoxaparin (+) group (n = 53). Short-term surgical results including venous thromboembolism (VTE) and portal vein thrombosis (PVT) were compared. Results: In the enoxaparin (+) group, the patients' age (65 vs. 69 years; p = 0.01) and BMI (22.9 vs. 24.4; p < 0.01) were significantly higher. According to the symptomatic VTE, symptomatic pulmonary embolism occurred in one patient (0.4%) in the enoxaparin (-) group, but the complication rate was not significantly different (p = 0.63). The complication rate of PVT was significantly lower in the enoxaparin (+) group (10 vs. 2%; p = 0.04). The independent risk factors for PVT were an operation time ≥ 300 minutes (Odds ratio 6.66) and non-treatment with enoxaparin (Odds ratio 2.49). Conclusions: Postoperative anticoagulant therapy with enoxaparin could prevent PVT in patients who underwent hepatic resection for liver cancers.

UR - http://www.scopus.com/inward/record.url?scp=84908120969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908120969&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2014.07.038

DO - 10.1016/j.thromres.2014.07.038

M3 - Article

C2 - 25156238

AN - SCOPUS:84908120969

VL - 134

SP - 826

EP - 831

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 4

ER -